![]() |
Name |
4-Hydroxy-3-methoxyphenethylene glycol triTMS
|
Molecular Formula | C18H36O4Si3 | |
IUPAC Name* |
[4-[1,2-bis(trimethylsilyloxy)ethyl]-2-methoxyphenoxy]-trimethylsilane
|
|
SMILES |
COC1=C(C=CC(=C1)C(CO[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C
|
|
InChI |
InChI=1S/C18H36O4Si3/c1-19-17-13-15(11-12-16(17)21-24(5,6)7)18(22-25(8,9)10)14-20-23(2,3)4/h11-13,18H,14H2,1-10H3
|
|
InChIKey |
AAFYLSSHQRPLSR-UHFFFAOYSA-N
|
|
Synonyms |
4-Hydroxy-3-methoxyphenethylene glycol triTMS; (4-Hydroxy-3-methoxyphenyl)ethylene glycol tris(trimethylsilyl) ether; 4-Hydroxy-3-methoxyphenylglycol, 3TMS derivative; 1,2-Ethanediol, 4-hydroxy-3-methoxyphenyl, tris-TMS; [[1-[3-Methoxy-4-[(trimethylsilyl)oxy]phenyl]-1,2-ethanediyl]bis(oxy)]bis(trimethylsilane); 4-(3-Methoxy-4-[(trimethylsilyl)oxy]phenyl)-2,2,7,7-tetramethyl-3,6-dioxa-2,7-disilaoctane #; 68595-81-3
|
|
CAS | NA | |
PubChem CID | 530366 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 400.7 | ALogp: | 5.7 |
HBD: | 0 | HBA: | 4 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 36.9 | Aromatic Rings: | 1 |
Heavy Atoms: | 25 | QED Weighted: | 0.49 |
Caco-2 Permeability: | -5.274 | MDCK Permeability: | 0.00001420 |
Pgp-inhibitor: | 0.108 | Pgp-substrate: | 0.017 |
Human Intestinal Absorption (HIA): | 0.5 | 20% Bioavailability (F20%): | 0.082 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.002 | Plasma Protein Binding (PPB): | 98.66% |
Volume Distribution (VD): | 3.065 | Fu: | 13.26% |
CYP1A2-inhibitor: | 0.562 | CYP1A2-substrate: | 0.986 |
CYP2C19-inhibitor: | 0.228 | CYP2C19-substrate: | 0.939 |
CYP2C9-inhibitor: | 0.294 | CYP2C9-substrate: | 0.891 |
CYP2D6-inhibitor: | 0.062 | CYP2D6-substrate: | 0.88 |
CYP3A4-inhibitor: | 0.117 | CYP3A4-substrate: | 0.661 |
Clearance (CL): | 2.787 | Half-life (T1/2): | 0.238 |
hERG Blockers: | 0.237 | Human Hepatotoxicity (H-HT): | 0.018 |
Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.041 |
Rat Oral Acute Toxicity: | 0 | Maximum Recommended Daily Dose: | 0.076 |
Skin Sensitization: | 0.941 | Carcinogencity: | 0.043 |
Eye Corrosion: | 0.996 | Eye Irritation: | 0.95 |
Respiratory Toxicity: | 0.604 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001149 | ![]() |
0.476 | D01JFT | ![]() |
0.250 | ||
ENC001399 | ![]() |
0.476 | D09GYT | ![]() |
0.235 | ||
ENC001123 | ![]() |
0.476 | D0R0FE | ![]() |
0.228 | ||
ENC001122 | ![]() |
0.434 | D0Q9ON | ![]() |
0.226 | ||
ENC000530 | ![]() |
0.333 | D01SAT | ![]() |
0.225 | ||
ENC001404 | ![]() |
0.326 | D0NJ3V | ![]() |
0.225 | ||
ENC001401 | ![]() |
0.324 | D0VU8Q | ![]() |
0.216 | ||
ENC001363 | ![]() |
0.301 | D02XJY | ![]() |
0.213 | ||
ENC001270 | ![]() |
0.294 | D01FFA | ![]() |
0.209 | ||
ENC001373 | ![]() |
0.284 | D02LZB | ![]() |
0.207 |